Management of Acute Heart Failure: Contribution of Ultrasound Daily "in Bed Patient" Adjustment on Therapy With Impact Measure on re Hospital Rate During 30 Days (JECICA)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Heart Failure

Treatments: Procedure: Transmitral flow estimation

Study type: Interventional

Funder types: Other

Identifiers

NCT02892227

2016-A00635-46 (Other Identifier)

AOI/2015/JER-01

Details and patient eligibility

About

Our hypothesis: a daily bedside echocardiographic assessment, protocolized, simple and reproducible estimation of filling pressures with an evaluation of mitral inflow and the inferior vena cava, allow a more reliable estimate of the true blood volume of the patient and thus lead to a therapeutic adjustment more suitable.

This therapeutic adjustment closer to patient's needs would impact fewer readmissions at 30 days and mortality, less alteration of biological parameters myocardial, kidney and liver.

Enrollment: 250 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

The patient or his representative must be given free and informed consent and signed consent.

• The patient must be affiliated or beneficiary of a health insurance plan.
• The patient is available for a follow-up 6 months.
• The patient is of age or older (>) 18.
• Patients hospitalized for acute heart failure who received at least 40mg of furosemide IV.
• Patient with impaired LVEF <50%.
• Patient with Nt-proBNP values> 1200pg / ml.

Exclusion criteria

• The subject takes part in another study.

  • The subject is exclusion period determined by a previous study.
  • The subject is under judicial protection.
  • The subject or his representative refuses to sign the consent.
  • It is not possible to give the subject or his representative informed information.

Non-inclusion criteria for those diseases or conditions associated (s) interfere (s):

• The patient is pregnant or is breastfeeding.
• The patient is already included in a surveillance program (PRADO, OSICAT).
• Patient with a mechanical or biological mitral prosthesis.
• History of mitral stenosis.
• severe valvular surgery with maturity in months (<30 days).
• chronic renal impairment on dialysis.
• High grade AV block (AVB and BAV3 2/1).
• Hypertrophic cardiomyopathy.
• Cardiogenic shock.
• Contraindications to furosemide.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

250 participants in 2 patient groups

JET ECHO

Experimental group

Description:

Transmitral flow estimation

Treatment:

Procedure: Transmitral flow estimation

NO JET ECHO

No Intervention group

Description:

no bedside echocardiography